○ The agreement is to fill and finish the Moderna COVID-19 vaccine bulk to produce hundreds of millions of doses to supply them to the world. □ First, Samsung Biologics and Moderna signed a CMO agreement on COVID-19 vaccine. ○ The event involved the signing ceremony of four MoUs and agreements among the Korean government and US and Korean companies. * (Main Participants) Minister of the Health and Welfare, Kwon Deok-cheol, Minister of Trade, Industry, and Energy Moon Sung-wook, chairman of SK group Chey Tae-won, CEO of Samsung Biologics John Rim, Secretary of Health and Human Services Xavier Becerra, CEO of Novavax Stanley Erck, and CEO of Moderna Stephane Bancel. □ With the participation of President Moon Jae-in, Minister of the Health and Welfare Kwon Deok-cheol and Minister of Trade, Industry, and Energy Moon Sung-wook held the ROK-US Vaccine Partnership Event at Willard InterContinental Hotel Washington, DC on Saturday, May 22 10AM local time, Saturday 11PM in Korean time to strengthen vaccine cooperation between the two countries. ○ Additionally, the ROK is expected improve its vaccine development and production capabilities to emerge as a global vaccine hub by increasing cooperation in vaccine production and R&D between the two countries. ○ By carrying out its crucial role as a vaccine supplier to relive the global vaccine shortages, the Republic of Korea is expected to improve the global awareness on its excellent production capabilities, human resource management, and quality control and to contribute to overcome the COVID-19 pandemic and return to normal life earlier. □ With the establishment of the KORUS Global Vaccine Partnership, the ROK and the US are expected to strengthen their global partnership beyond the traditional bilateral relationship to jointly fight against global public health emergencies. ○ They agreed to launch the KORUS Global Vaccine Partnership Experts Group comprised of scientists, experts, and officials from each government to back the partnership on the working level. In addition, the two countries will actively carry out scientific and technological cooperation to improve infectious disease response capabilities against global public health emergencies. supply of raw materials needed for vaccine production globally. ○ Specifically, in order to meet growing demand for COVID-19 vaccines, the two countries will bolster their support for increasing production capacity in Korean manufacturing facilities rapidly, and expanding the U.S. ○ The KORUS Global Vaccine Partnership is established to speed up the production and global supply of COVID-19 vaccines in times of global vaccine shortages by combining each of their strengths, which include the United States' vaccine development technologies and its capacity to supply raw materials and the ROK's vaccine manufacturing capabilities. □ The importance of the role of the ROK as a global vaccine production base is growing as it is producing and supplying Astrazenca, Novavax and Sputnik V COVID-19 vaccines to the world. ○ The two leaders agreed on establishing the KORUS Global Vaccine Partnership on Friday, May 21 in the summit meeting. □ On the occasion of President Moon Jae-in's visit to the United States from May 19 to May 23, cooperation between the governments and companies of the Republic of Korea and the United States is strengthened for the ROK to emerge as a global vaccine hub. Bilateral talks between health ministers, boosting ROK-US cooperation for global vaccine hub.
The expansion of vaccine production and supply of raw materials, the establishment of a comprehensive vaccine partnership which include cooperation in science and technology. The Establishment of ROK-US Global Vaccine Partnership
0 kommentar(er)
